Sponsors (22)
The bill speeds veterans' access to FDA‑approved non‑opioid pain therapies and makes VA planning more predictable, but does so at potential cost to VA budgets and with administrative strain from a tight implementation deadline.
Veterans will get faster access to FDA‑approved non‑opioid drugs and biologics for acute and postoperative pain, expanding non‑opioid pain‑management options and potentially reducing veterans' opioid exposure, addiction risk, and overdose risk.
VA pharmacies and health systems (and therefore veterans) gain predictable, defined timelines for adding new non‑opioid therapies, improving procurement, inventory planning, and readiness to deliver new treatments.
VA patients and services — and taxpayers — could face financial pressure because the VA must absorb implementation and acquisition costs from existing budgets and may be required to add high‑cost products without a VA cost‑effectiveness review, potentially reducing funds for other VA programs or increasing government spending.
The 90‑day mandatory implementation deadline may strain the Department of Veterans Affairs' administrative capacity, risking rushed formulary decisions, logistics challenges, or uneven rollouts that could negatively affect care delivery.
Based on analysis of 2 sections of legislative text.
Introduced November 19, 2025 by Shelley Moore Capito · Last progress November 19, 2025
Requires the Department of Veterans Affairs to add FDA-authorized non-opioid drugs and biologic products for acute and postoperative pain to the VA national formulary on a specific schedule tied to Medicare payment eligibility or FDA approval. It defines which products count as “non-opioid,” bars use of the Cost of War Toxic Exposures Fund to pay for implementation, and directs the VA to put the changes into effect within 90 days of enactment.